Full Name | Veopoz™ (pozelimab-bbfg) |
Drug | Veopoz |
Manufacturer | Regeneron Pharmaceuticals |
Route of Administration | Intravenous |
Site of Care | Healthcare Facility |
Approved Indication | The treatment of adult and pediatric patients 1 year of age and older with CD55-deficient protein-losing enteropathy (PLE), also known as CHAPLE disease |
Disease | CD55-deficient protein-losing enteropathy (CHAPLE) Disease |
Therapeutic Area | Allergy & Immunology, Hematology |
Enrollment Form Link | Veopoz Enrollment Form |
Phone Number | 800-438-2375 |
Fax Number | 877-440-0891 |
Product Website | veopoz.com |
About CD55-Deficient Protein-Losing Enteropathy (CHAPLE) Disease
CHAPLE disease (also known as CD55 deficiency with hyperactivation of complement, angiopathic thrombosis, and protein losing enteropathy, or CD55-deficient protein-losing enteropathy) is an ultra-rare hereditary condition characterized by an inability to regulate complement activity because of mutations in the CD55 gene. In most patients, this leads to potentially life-threatening symptoms beginning in infancy, including abdominal pain, bloody diarrhea, vomiting, malnutrition, slow growth, and edema. There are fewer than 100 patients worldwide who are known to have CHAPLE disease.